Competitors in the market for the treatment of coronary artery disease must face a litany of alternative technologies targeted at this patient caseload. Despite the successes of drug-eluting stents (DES) in producing results that are cost- and outcome-competitive compared to coronary artery bypass grafting, the drive for less invasive alternatives, improved clinical outcomes and other benefits will continue to produce technology alternatives.
In addition to drug-eluting, bare metal and bioresorbable coronary stents, a range of novel stent technologies are under development in the market:
- bioactive coatings
- antibody coatings
- biomimetic coatings (biocompatible and thromboresistant)
- hydrophilic coatings to facilitate stent delivery
- titanium-nitride-oxide coating
- genetically engineered bioactive
- coatings to induce endothelial cell growth
- pericardium-covered stents
- beta-radiation emitting stents
- polymer coatings engineered to be pulsatile, biostable
- anti-thrombotic, anti-inflammatory, bacterial-resistant coating
- stents engineered with embolic protection capability
Development is also not limited to the above stent technologies, as technologies for drug-eluting balloons, robotic CABG and a wide range of other technologies are the focus of many competitors seeking to displace some of the billions of dollars spent on coronary stents.
See the 2009 MedMarket Diligence report #C245, "Worldwide Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017."
Posted via email from medmarket's posterous
